Q3 2020 Sales Performance

Nucala: market leadership with upside opportunity Leading in eosinophilic indications ■ £251m in Q3, +29% CER; remains the IL-5 market leader globally ■ Growth opportunity: 12-24m with SEA¹ globally but majority undertreated ~420k patients in US; only 27% currently receive a biologic Rapid indication expansion: Paediatric patients First biologic with auto-injector for at home use First biologic approved for EGPA² and HES³ First anti IL-5 with positive Ph3 data in NP4 Phase 3 study in COPD ongoing Delivers proven efficacy by precisely targeting IL-5 to reduce eosinophils to normal levels Global leader in IL-5 market share Moving Quarterly Total (MQT) Market Share* GSK - Nucala Competitor X gsk 72% 64% 62% 59% 56% 57% 44% 43% 41% 38% 36% 28% 1. Severe Eosinophilic Asthma 2. Eosinophilic granulomatosis with polyangiitis 3. Hypereosinophilic syndrome 4. Nasal Polyps US Germany France Italy Spain Japan * Market share data sources: US (IQVIA DDD+ and Xponent data), Germany ("Sell Out Units ZE" from German PADDS- Pharmascope and "Zaehleinheit" from German PADDS-DKM dataset), France (IQVIA & GERS), Italy (IQVIA Volume Data), Spain (Atrys Health Severe Asthma - Biologic Market), Japan (IQVIA PEQ Data) 242

View entire presentation